Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study.
Phase of Trial: Phase IV
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 01 Apr 2016 Results (n=1018) published in the International Journal of Clinical Practice.
- 11 Oct 2011 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.